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pharmaceutical arena
Marianne Scheffler
Danbury Pharmacal, Inc., 12 Stoneleigh Avenue, Carmel, New York 10512, USA
Robotics was introduced by Danbury Pharmacal, Inc. in 1987 in
order to improve laboratory throughput for several new products.
The author uses Danbury Pharmacal’s experience to give an
overview ofvarious issues, such as acceptance by senior management
and chemists, political confrontation, validation and product
throughput.
Introduction
The pharmaceutical industry, both generic (multi-
source), as well as PMA (’Brand’) firms have a primary
obligation to provide to the user (patient) finished dosage
forms which meet all mandated standards for identity,
purity, strength, and quality. A key difference between a
generic pharmaceutical or multisource company and a
major PMA firm are the larger number and greater
variety of products manufactured by the generic firm.
The pharmaceutical industry continues to be challenged
with stricter government regulations, which has placed
increasing demands on firms for better and faster
analytical testing capabilities. Pressure to meet produc-
tion schedules without compromising product quality
often becomes the driving force to improve laboratory
productivity. Improving laboratory productivity is com-
plicated by shorter product life-cycles, coupled with the
continuing changes in specifications and test methods
made by the FDA and the USP/BP/PF etc. Each time a
change in requirement occurs, a whole battery of time-
consuming activities ensues: validation of modified test
methods, verification of compliance to the new specifica-
tions, updating laboratory documentation etc.
Increased productivity can often be achieved from the
existing laboratory staff by allowing individuals to
concentrate on the problem areas, while the laboratory
equipment performs the repetitive work. These include
the routine use of autosamplers for titrators, HPLC
systems, and GC systems, automated dissolution appara-
tus, etc. The author’s company, like most firms, has also
tried to achieve this goal by introducing robotics. A
Zymark Pytechnology II robot was purchased in 1987 by
Danbury Pharmacal. The robot pysections were de-
veloped to perform content uniformity analysis with
detection by a Diode Array UV/Vis spectrophotometer.
Content uniformity testing is one of the major time-
consuming and repetitive tasks for the chemist.
The development and continued success of Danbury
Pharmacal’s robotics efforts resulted from a continuously
increasing work-load, coupled with the presence of
’technical champions’ for automation. This paper exam-
ines some key issues that the organization’s automation
effort raised.
A) Hand G H) Flack #3 Test Tube Rack
B) Liquld/Uquid Station I) Hand O
C) Rack #1. Fleaker Rack J) Ra #4 Test Tube Rack
D) Ooital Shaker K) D & D
E) Hind C L) Spe SIP
F) Rack #2 Fleaker Rack M) Balance
G) Fleakar Capng Station Off The Pie
1. Diode An’ay Speclropholomelar
2. MLS Slallon
3. Power Even! Control
4. CRT
Figure 1. Zymark Pytechnology II robot.
Commitment
The most important factor in the success of any
laboratory robotics system is support and commitment
by management. Unrealistic commitments are often
made to managers about the advantages and productivity
of robotics systems. This is particularly true when a
robotic system is introduced as a research tool rather than
as a turn-key acquisition for a particular assay. Soon after
the initial acquisition ofthe robot at Danbury Pharmacal,
the robotic staff chemist assigned to validate and
automate methods on the robot became urgently needed
for other tasks. When significant delays, due to unpre-
dicted problems, occur during the development of a
robotic assay intended to replace a labour-intensive
manual assay, management’s enthusiasm rapidly dimin-
ishes. At this point, purely technical issues become
political issues. Questions arose such as ’Why is the robot
not producing’, ’When will it be on-line?’, and ’Why have
we spent all this money for the robot to collect dust?’.
However, clear thinking about the best type of appli-
cation for the robot often leads to identifying the proper
types of methodologies to automate. Such was the case
with the author’s company and the robot was put back to
effective use in the laboratory.
(C) Zymark Corporation 1992
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Staffing and location
Staffing
Staffing was a real problem in implementation: whether
to have a computer programmer or a chemist. It was
decided that successful automation of a sample prep-
aration and analysis would require close involvement of
an individual in the scientific discipline. In chemistry, for
example, many ofthe failures ofautomation can be traced
to situations where engineers or computer programmers
were expected to make decisions and judgments about
chemical procedures. Of course, a knowledge of automa-
tion techniques was important too. However, it appears
to be easier for a chemist to understand the automation
needs than it is for an engineer or a computer program-
mer to understand all the nuances of chemistry.
Location
The robot was located between the quality control (QC)
and research and development (R & D) laboratories. The
room. was not the most suitable for making repairs to the
robot, but it is operational. A compressed air line was
installed to handle the liquid/liquid and balance pysec-
tions. Laboratory reagents are prepared in either the QC
or R & D laboratory and brought into the robotic room
for the robot to handle. The ideal situation would be to
design the laboratory space prior to the installation of the
robotic system. For instance, all services, such as water,
air, vacuum, temperature control, ’360’ access, etc.,
should be considered and instituted as part of the
laboratory design. Ample room should also be provided
for any future expansion.
Approaching automation
To implement robotics or not? The key issue in selecting
the appropriate pysections for the robot is to first consider
what product(s) might be suitable for automation. Issues
such as how often is the product being manufactured,
and, how complex is the manual methods, should all be
taken into consideration. A careful review must be
conducted to search for a robotics application so that
appropriate pysections can also be identified and pur-
chased. The author’s company’s robot was purchased,
instead, with a process in mind, content uniformity, not a
product. However, not all products would be amenable to
automation on this robot due to the limitations of the
analysis detection by a UV/Vis spectrophotometer.
Indeed, many high volume products are analysed by
HPLC. The robotic staff chemists have identified four
product lines that can be considered for automation. In
summary, management must recognize that the best
applications which can benefit may not be attainable with
the equipment initially purchased, and to understand the
reasons why implementation is not always easy, even if
the application is appropriate.
Another type of political issue that often accompanies the
installation of robotics in a busy QC laboratory environ-
ment is ’job security’. Many chemists still feel that
robotics will replace their jobs. Others say that the robot
could not be as precise as the chemist. One way of
changing this thinking is to show that the chemists can
now perform the other tasks required to complete the
analysis work for the product, or concentrate on other
projects. Another approach is to ask whether the chemists
would prefer to perform manual injections on an HPLC
system or use an autosampler--the majority of chemists
will choose the autosampler. With time, a full and
complete acceptance of robotics will be inevitable.
Currently, only one product line has been released for
routine testing by the present robot, and several other
products are going through the final stages ofautomation
validation. Other technologies are concurrently being
investigated by the robotic staff chemists to aid the
automation effort, to reduce chemist analysis time, and
still manage the large volume ofproducts being manufac-
tured. The issues of automating other methods are also
being considered and reviewed.
Robotics is not the answer to all laboratory problems. An
autorffated method could often have a longer robotic
analysis time than a chemist performing the task
manually. However, it must be taken into consideration
that robots do not take lunch breaks, coffee breaks,
vacation, or chat with their fellow robots. They can
operate 24 hours a day, seven days a week, 365 days a
year.
By automating an analytical method, the human error
factor has been reduced. Automation eliminates possible
errors, such as incorrect dilutions, weighings, miscalcula-
tions, and transcription errors. The reliability of any
robotic or automated method ultimately is a direct
reflection on the creative chemist who automated the
methods and successfully validated the process.
Validation
Validation of the robot is accomplished in two stages.
Stage one involves the validation of the bench-top
configuration. It is important to remember that the
specific application for the pysection requires thorough
examination for validation considerations. The bench-
top validation can be elaborate and complex, or a
simplistic approach can be implemented. We have given
this decision to the robotic staff chemist performing the
validation. The bench-top validation process provides the
robotic staff chemist experience in all phases of the
robotic operation required for programming, and allows
them to become familiar with the Pytechnology II robot.
The robot’s pysections are as follows:
(2) 16 x 100 mm test tube racks
(1) Fleaker Capping Station
(1) Orbital Shaker
(1) Spec Sip Station
(1) Dilute and Dissolve
(1) Hand D
(1) 0’2 ml-l.0 ml Hand G
(1) Hewlett-Packard Diode UV/Vis Spectrophotometer
38M. Scheftter Managing robotics in the generic pharmaceutical arena
(2) 250 ml Fleaker Cap Racks
(1) Liquid/Liquid Pysection
(1) Mettler Balance
(1) Master Lab Station (MLS)
(1) Power & Event Controller
(1) Hand C.
Stage two involves creating the automated method and
validating the automated process; the two validation
stages need to be further explained.
Benchtop configuration validation
The benchtop validation consisted of grouping various
robotic procedures to validate several pysections simulta-
neously. Some of the benchtop programs are also utilized
during the validation process for automating a method.
For example, a typical benchtop validation program
consists of utilizing the test-tube racks, dilute and
dissolve, analytical balance, and the MLS station.
Grouping several robotic functions gives the ability to
assure, and monitor simultaneously, the capability of the
sample numbering sequence, grasping and placement of
an appropriate test-tube, and monitoring the accuracy of
dispensing a liquid in correlation to the weight received
on the analytical balance. In this case, water was used as
the solvent to conduct the benchtop validation, but this
program can also be employed for any other solvent
system that is desired. An example of the data collected is
displayed in table 1. Benchtop validation is performed
upon installation, or if the unit must be disassembled and
moved to a new location, or if the benchtop configuration
changes due to the installation of a new pysection,
upgrades, and/or major repairs.
Validating the automated method
After successfully validating and documenting the bench-
top configuration, the creation of a program for automat-
ing a manual method begins. We approached this by
simulating robotically what the chemist would perform
manually with minimal process modifications. A final
and important step before routine use of any automated
sample preparation system is to validate the integrity of
the method. The object of the validation test is to prove
that there are no procedural errors in the automated
sample preparation method. The obvious analysis is to
verify that the samples at the end of the process are in a
form suitable for their intended use. The less obvious
factor is the need to be sure that there are no significant
variables that affect the samples that may not be
controlled.
Stage two now involves validating the automated
method. The automated method was adapted from an
established manual method. Linearity, accuracy, preci-
sion, recovery, and equivalency of the automated method
were compared with the manual method.
During the validation process, difficulty was found
recovering the analyte from the product excipients. To
correct the recovery problem, a slight modification of the
sample extraction preparation was implemented. It was
noticed, during other product validations, that the
limiting factor in automating the method was due to the
Table 1. MLS Syringe B Validation.
MLS syringe B dispensing 2"0 ml of water
Sample number Sample weight Corrected volume for
density
1"9940 g 2"002 ml
2 1"9936 g 2"002 ml
3 1"9932 g 2"001 ml
4 1"9933 g 2"001 ml
5 1"9943 g 2"002 ml
Mean volume SD % RSD Accuracy
2"0017 0"0004 0"0209 0"0843
MLS syringe B dispensing 5"0 ml of water
Sample number Sample weight Corrected volume for
density
6 4"9963 g 5"016 ml
7 4"9957 g 5"016 ml
8 4"9960 g 5"016 ml
9 4"9957 g 5"016 ml
10 4"9955 g 5"016 ml
Mean volume SD % RSD Accuracy
5"0159 0"0003 0"0056 0"3181
MLS syringe B dispensing 7"0 ml of water
Sample number Sample weight Corrected volume for
density
11 6"9992 g 7"027 ml
12 6"9984 g 7"027 ml
13 6"9977 g 7"026 ml
14 6"9978 g 7"026 ml
15 6’9976 g 7"026 ml
Mean volume SD % RSD Accuracy
7"0262 0"0006 0"0085 0"3749
MLS syringe B dispensing 10"0 ml of water
Sample number Sample weight Corrected volume for
density
16 10"0086 g 10"049 ml
17 10"0089 g 10"049 ml
18 10’0091 g 10"049 ml
19 10"0088 g 10"049 ml
20 10"0087 g 10"049 ml
Mean volume SD % RSD Accuracy
10"0490 0"0002 0"0019 0"4902
orbital shaker. This was concluded by breaking down the
various robotic steps and carrying on the remainder ofthe
process manually to identify the probable cause. The
orbital shaker dissolves the solid dosage form, but it does
not use the same action as a mechanical shaker or
sonicator. However, there are variations that can be
implemented, and documented, to the sample prep-
aration procedure that can alleviate these limitations.
Performing the equivalency portion of the validation for
the manual methods versus the automated method,
provided very encouraging data. Five randomly manu-
factured lots were analysed for the two potencies. The
products were analysed for content uniformity and assay
by both methods to determine the comparability of the
methods. Again, content uniformity is performed on 10
individual dosage units for an existing batch, and two
sample weights are taken from a composite blend of 20
tablets for the assay. Zymark’s robot proved to be
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Table 2. Analytical data for content uniformity
Standard number Std. wgt(gm) Standard abs.
0"0532 0"5434
Sample number Sample wgt(gm) Sample abs. Conc.(mg/tab) %label
0"5055 0"5569 98"140 98.14
2 0"5120 0"5715 100"716 100"72
3 0"5080 0’5806 102"318 102’32
4 0"5064 0"5859 103"240 103"24
5 0’5108 0"5881 103"641 103"64
Standard number Std. wgt(gm) Standard abs.
2 0"0532 0"5595
Sample number Sample wgt(gm) Sample abs. Conc.(mg/tab) %label
6 0"5090 0"5747 101"270 101"27
7 0"5095 0"5772 101"710 101"71
8 0’5146 0’5789 102"006 102"01
9 0"5086 0"5766 101"606 101"61
10 0"5114 0"5774 101"754 101"75
Standard number Std. wgt(gm) Standard abs.
3 0"0532 0"5542
Calc. tab. mean. wt SD %RSD Avg.(%label)
0"5096 1"506 1"482 101"64
Assay number
2
Standard number
4
Avg. tab. wgt (gm)
0"5127
Chemist:
Date: July 16, 1991
Product:
Status: Coated
Potency: 100 mg
Lot number:
Book number:
Page number(s)
Standard lot number: 84
Standard purity: 0’9980
Sample wgt (gm)
0"5150
0"5160
Std. wgt (gm)
0"0532
Avg. conc.
100"275
Sample abs.
0’5719
0"5773
Standard abs.
0"5552
Avg. (% label)
100"27
Conc. (mg/tab) % label
99"904 99"90
100"646 100"65
accurate and precise: statistically there was no significant
difference noted between the data collected from the
manual method versus the robotic method. The critical
parameter indicated that there was a 95% confidence
level performing a paired t-test.
Documentation
Documentation should be prepared as the system pro-
gram parameters are being developed, and not as a
separate entity at the end ofa project. The objective ofthe
documentation is to record all experiments that occurred
during the validation process. A final validation report
should document the events and demonstrate the results
obtained. The documentation process also allows a new
person to operate and maintain the system.
Robotic analysis
Danbury Pharmacal has released one product line using
the robotic results obtained for both assay and content
uniformity. This product is in the form of a film-coated
tablet; after the laboratory submits the results for
releasing the core product, it is then film-coated by the
manufacturing department, and another random sam-
pling of the same lot is sent to the laboratory for analysis.
The chemist’s involvement in the robotic process is
approximately 45 minutes. This time is spent replenish-
ing disposable items such as test-tubes, pipette tips and
filters, placing the samples and standards in the appropri-
ate positions, and preparing the sample extraction
preparation solution. Finally, the chemist documents the
data in the laboratory notebook.
Full data reports are calculated and generated by the
robot so the chemist can concentrate on interpreting the
data. An example of a report generated by the robot is
given in table 2. All pertinent reporting information for
the robot has been programmed to be presented on a
single piece of paper. This includes the weights, absor-
bance readings, percentage of label results, statistics,
operator, date, and the laboratory notebook volume and
page where the results can be located.
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Multi-task events
As was stated previously, the robot is releasing the
product for content uniformity and assay for this
particular product line. To properly manage the work-
load for the robot, overnight release testing is performed.
A product is placed on the robot in the late afternoon and
so the robot can operate overnight unattended. The
chemist retrieves the final results the following morning
and reviews the data to ensure that no system problems
have occurred.
Danbury Pharmacal’s robot is utilized during the day to
validate other products. It is essential to take into
consideration, while automating other products on the
same robot, the possibility of contamination. Controlling
the number of different methods dedicated to the robotic
system would minimize, if not reduce, the possibility of
contamination. Typically, analyses that have like systems
for the solvent preparation media are used for the robot.
In addition, a wash program has been written and
instituted to flush all reagent lines, syringes, and
flowcells, with copious amounts of wash media after the
completion of the automated analysis.
The ideal situation would be to have two identical robotic
systems. One unit would be utilized for the development
process for automating a method, and the other unit
would be dedicated to releasing the product. The
program disks could be transferred to the second unit
once the validation process and report had been lnalized
and approved. Currently, Danbury Pharmacal is not in
this situation. It makes it quite difficult to time-manage
the validation and releasing products. The second
automated product method is near completion and the
company is now gearing for a third product validation.
Conclusion
The author’s company’s experience with robotics, during
the past few years, has been a challenging but positive
one. With aid from the dedicated staff, and continued
support from the management robotics will succeed and
continue to expand into different facets in the
organization.
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